Latest [Sep 08, 2021] RAPS RAC-GS Exam Practice Test To Gain Brilliante Result
Take a Leap Forward in Your Career by Earning RAPS RAC-GS
NEW QUESTION 23
Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a
reimbursement agency?
- A. "Has the product been approved for mor&4nan 10 years?"
- B. "Is the product an established gold standard?"
- C. "Is the product profitable for the manufacturer?"
- D. "Is the product better than currently available alternatives?"
Answer: D
NEW QUESTION 24
What is the LAST stage in the development of a quality risk management process for a medical device?
- A. Risk reduction
- B. Risk evaluation
- C. Risk acceptance
- D. Risk analysis
Answer: C
NEW QUESTION 25
In order to develop a global drug product, what is the MOST important environmental characteristic to
consider in the country of intended use?
- A. Product requirements
- B. Product registration
- C. Product stability
- D. Product formulation
Answer: C
NEW QUESTION 26
During a regulatory authority inspection of a manufacturing site, the inspector observes that one of the
medicinal products manufactured at the site is not GMP compliant. The product Is distributed globally.
Which of the following is the most appropriate action to take FIRST?
- A. Assess the potential safety risk.
- B. Send a "Dear Dr." letter to customers.
- C. Withdraw the affected product from the markets.
- D. Notify the global regulatory authorities.
Answer: D
NEW QUESTION 27
Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control
activities for a medical device?
- A. Fishbone analysis
- B. Quality by design analysis
- C. Failure modes, effects, and criticality analysis
- D. Fault tree analysis
Answer: C
NEW QUESTION 28
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage
should the manufacturer be able to trace back the product?
- A. Product distribution
- B. Individual plasma donation
- C. Plasma fractionation
- D. Plasma pooling
Answer: A
NEW QUESTION 29
As a member of the product launch review committee, a regulatory affairs professional discovers a major
issue with the labeling of a product prior to production. In addition to informing the committee, which is the
BEST approach to address the issue?
- A. Correct the label text.
- B. Inform the regulatory authorities.
- C. Abort the product launch.
- D. Delay the start of product production.
Answer: B
NEW QUESTION 30
During routine surveillance, a regulatory authority sent a company the following communication:
"Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product.
The regulatory authority is evaluating these issues to determine the need for any regulatory action."
Which action would be the most appropriate FIRST step for the company to take?
- A. Contact the regulatory authority to argue that its conclusions are wrong.
- B. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.
- C. Wait for the regulatory authority's final publication on its findings.
- D. Contact the regulatory authority to discuss its findings.
Answer: D
NEW QUESTION 31
Why is it necessary to run supplemental safety pharmacology studies?
- A. To evaluate potential adverse pharmacodynamics effects not addressed by the core battery
- B. To comply with regulatory authority requirements related to clinical studies
- C. To substitute the utilization of GLP
- D. To provide adverse reaction reports and the results of the statistical data to the regulatory authority
Answer: A
NEW QUESTION 32
In a distribution contract for high-risk medical devices, which of the following regulatory requirements is
the MOST important for the distributor?
- A. Service operation procedures .
- B. Local reimbursement requirements
- C. Written procedure for product traceability
- D. Training program for sales people
Answer: D
NEW QUESTION 33
Which of the following situations does NOT require rapid communication to regulatory authorities?
- A. A lack of efficacy with a medicinal product used in treating a life-threatening disease
- B. A clinically important increase in the rate of occurrence of an "expected." but serious ADR
- C. A major safety finding from a newly completed animal carcinogenicity study
- D. A statistically significant increase in the number of deaths in an animal dose finding study
Answer: B
NEW QUESTION 34
A global company has obtained a patent in a specific country for a newly marketed product. What would
be the BEST advice In order to protect the patent in other countries?
- A. File patents of interest in target countries.
- B. Use the Madrid system.
- C. File design patents in target countries.
- D. Use the community patent system.
Answer: A
NEW QUESTION 35
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the
following?
- A. Inadequate training
- B. Late and/or incorrect deliverables
- C. Causes of non-conformities
- D. Adverse environmental impacts
Answer: C
NEW QUESTION 36
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject's hospitalization is due to an unscheduled hip operation.
- B. Subject is hospitalized due to complications of the product administration.
- C. Subject's hospitalization is prolonged during the clinical trial.
- D. Subject is hospitalized for the purpose of product administration.
Answer: D
NEW QUESTION 37
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the
manufacturing process. Which of the following stakeholders should be notified FIRST?
- A. Clinical affairs
- B. Quality improvement
- C. Quality assurance
- D. Regulatory agency
Answer: C
NEW QUESTION 38
A company is developing a new product for the global market. A new international guideline will
recommend relevant studies in the pediatric population, and the guideline will be effective before the
approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this
guideline on the successful registration of the new product?
- A. The company should initiate the required pediatric studies immediately to avoid costly delays to the
current registration plan. - B. The company should consult with relevant regulatory authorities to determine the potential impact on
the current registration plan. - C. The new guideline has no impact on the current registration plan since all relevant registration studies
are almost completed. - D. The new guideline has no impact on the current registration plan, but the company must be prepared to
defend its decision.
Answer: B
NEW QUESTION 39
The API used for an approved drug product conforms to international monograph specifications and local
pharmacopeia; however, the international monograph specifications of the API will be changing soon.
Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Confirm that the international monograph change is not related to local pharmacopeia.
- B. Prepare the international monograph change submission first and then prepare the local change when
required. - C. Analyze the impact of the international monograph change on the local pharmacopeia.
- D. Transfer the notice of the upcoming international monograph change to QA for further processing.
Answer: D
NEW QUESTION 40
A process is ultimately validated to ensure which of the following?
- A. The process meets the regulatory requirements.
- B. The process meets the quality system requirements.
- C. The process consistently produces the desired results.
- D. The process consistently meets the desired Quantity standards
Answer: C
NEW QUESTION 41
Company X and Company Y both have products for the treatment of rare genetic diseases. Company X
would like to acquire Company Y but does not know enough about Company Y to make an offer.
What is the MOST appropriate approach that Company X should take to acquire more information about
Company Y?
- A. Perform a thorough library search to gather detailed information on Company Y.
- B. Request the needed information from the Board of Directors of Company Y.
- C. Recruit a professional to gather confidential intelligence on Company Y.
- D. Enter into an agreement with Company Y to perform due diligence.
Answer: D
NEW QUESTION 42
A materials supplier informs a company that it intends to stop supplying a material critical to the
manufacture of the company's products. What action should the company take FIRST?
- A. Complete a gap analysis to identify options.
- B. Reformulate the products with a replacement material.
- C. Review the company's existing Quality Management System
- D. Qualify another supplier and execute a supplier agreement.
Answer: D
NEW QUESTION 43
What are the MOST important elements that global regulatory agencies want to know before approving a
new product for sale in their countries?
- A. Safety and failure risk
- B. Safety and effectiveness
- C. Quality and failure risk
- D. Quality and effectiveness
Answer: B
NEW QUESTION 44
A company is developing a line of products for which no ISO standard of performance is available. As a
result, the company wishes to propose developing such a standard. Whom should the company contact in
order to start the development of the new standard?
- A. The ISO national member body
- B. The ISO Secretariat
- C. The country's regulatory authority
- D. The ISO technical committee in charge of the area
Answer: A
NEW QUESTION 45
According to WHO, what are the temperature and humidity conditions for a Zone IVb long-term stability
study?
- A. 30 C and 35% RH
- B. 30c C and 65% RH
- C. 30: C and 75% RH
- D. 25: C and 60% RH
Answer: C
NEW QUESTION 46
Which of the following statements regarding the off-label use of drugs is CORRECT?
- A. The peer-reviewed literature can ensure high-quality off-label promotion of medications, thereby
increasing access to much needed drugs and devices. - B. The regulatory authority does not restrict physician prescribing for off-label indications or regulate the
manufacturer's promotion for such use. - C. Although the regulatory authority reviews and approves drugs for specific indications, the approval
does not limit the use of those drugs in clinical practice. - D. Sponsors are allowed to distribute publications about unapproved uses of approved drugs and devices
as long as the marketing application is under review by the regulatory authority.
Answer: C
NEW QUESTION 47
A company is currently marketing an implantable orthopedic medical device. The R&D department is
planning to change the material used for the implant. The R&D department states that the change does
not impact the safety and effectiveness of the product. What action should the regulatory affairs
professional take FIRST?
- A. Prepare regulatory submissions that detail the medical device's change in materials.
- B. No action is needed in this situation.
- C. Write a memo to file since the change does not impact product safety and effectiveness.
- D. Review the content of change and supporting data for the equivalency with the current material.
Answer: D
NEW QUESTION 48
......
Authentic Best resources for RAC-GS Online Practice Exam: https://www.guidetorrent.com/RAC-GS-pdf-free-download.html